Do basophil and eosinophil predominance, along with IL4R rs1801275 and IL4 rs2243250 variants, indicate a Th2 allergic immune tendency?

The coordinate elevation of basophils and eosinophils, paired with specific genetic variations in the interleukin-4 (IL-4) pathway, characterizes a highly active, self-sustaining Type-2 (Th2) allergic immune profile.

Clinical and genetic evidence

• Atopic susceptibility: The IL4R rs1801275 (Q576R) and IL4 rs2243250 (-589C>T) variants are established genetic drivers of Th2-skewed immune tendencies. Meta-analytic and clinical data link these polymorphisms to increased serum IgE, atopic asthma, and allergic rhinitis.
• Inflammatory indicators: Basophil and eosinophil predominance serves as a highly reliable marker for active type-2 tissue inflammation and clinical hypersensitivity.

Mechanistic pathways of Th2 activation

• Receptor hypersensitivity: The IL4R Q576R variant alters the IL-4Rα receptor chain structure. This modification amplifies downstream JAK-STAT6 signaling in response to IL-4 and IL-13, enhancing vascular cell adhesion molecule-1 (VCAM-1) expression, mucus production, and airway remodeling.
• Transcriptional upregulation: The IL4 -589C>T promoter polymorphism increases transcriptional activity and IL-4 expression. This excess cytokine signaling promotes naive CD4+ T-cell differentiation into helper Th2 cells and drives B-cell class switching to IgE.
• Feed-forward cellular loop: Basophils act as crucial early sources of IL-4 to initiate polarization. Simultaneously, IL-4 and IL-13 drive the release of epithelial eotaxins and stimulate type 2 innate lymphoid cells (ILC2s) to produce IL-5, which recruits and stabilizes eosinophils. Activated eosinophils then release additional IL-4 and IL-5, perpetuating chronic tissue inflammation.

Bottom line

• Basophil and eosinophil predominance reflects an active Type-2 allergic state that is mechanistically driven and amplified by the hyperfunctional signaling of the IL4R rs1801275 and IL4 rs2243250 genetic variants.